Immunocore Holdings plc
Immunocore Holdings plc is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors on October 15, 2026. There are 7 upcoming events on record.
Cash runway is approximately 191.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 8 concluded trials, 38% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 15, 2026 | Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Trial Milestone | Phase 1/Phase 2 |
| October 15, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| November 30, 2026 | Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers | Trial Milestone | Phase 1/Phase 2 |
| September 30, 2027 | Study of IMC-P115C in Advanced PRAME-Positive Cancers | Trial Milestone | Phase 1 |
| October 16, 2027 | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | Trial Milestone | Phase 3 |
| March 15, 2028 | Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | Trial Milestone | Phase 3 |
| November 15, 2030 | Study of IMC-S118AI in Type 1 Diabetes | Trial Milestone | Phase 1 |
Track IMCR alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open IMCR in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.